DK1991678T4 - Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer - Google Patents

Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer Download PDF

Info

Publication number
DK1991678T4
DK1991678T4 DK07750780.4T DK07750780T DK1991678T4 DK 1991678 T4 DK1991678 T4 DK 1991678T4 DK 07750780 T DK07750780 T DK 07750780T DK 1991678 T4 DK1991678 T4 DK 1991678T4
Authority
DK
Denmark
Prior art keywords
procedures
compositions
oligonucleotide formulations
oligonucleotide
formulations
Prior art date
Application number
DK07750780.4T
Other languages
Danish (da)
English (en)
Other versions
DK1991678T3 (en
Inventor
Eugen Uhlmann
Joerg Vollmer
Arthur M Krieg
Ulrike Samulowitz
Bernhard O Noll
Original Assignee
Rechtsanwalt Thomas Beck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38372127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1991678(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rechtsanwalt Thomas Beck filed Critical Rechtsanwalt Thomas Beck
Application granted granted Critical
Publication of DK1991678T3 publication Critical patent/DK1991678T3/en
Publication of DK1991678T4 publication Critical patent/DK1991678T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DK07750780.4T 2006-02-15 2007-02-15 Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer DK1991678T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77350506P 2006-02-15 2006-02-15
US85824006P 2006-11-09 2006-11-09
PCT/US2007/003964 WO2007095316A2 (en) 2006-02-15 2007-02-15 Compositions and methods for oligonucleotide formulations

Publications (2)

Publication Number Publication Date
DK1991678T3 DK1991678T3 (en) 2015-11-16
DK1991678T4 true DK1991678T4 (da) 2020-10-19

Family

ID=38372127

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07750780.4T DK1991678T4 (da) 2006-02-15 2007-02-15 Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
DK11183857.9T DK2405002T3 (en) 2006-02-15 2007-02-15 Compositions and methods for oligonukleotidformuleringer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11183857.9T DK2405002T3 (en) 2006-02-15 2007-02-15 Compositions and methods for oligonukleotidformuleringer

Country Status (8)

Country Link
US (2) US20080045473A1 (enExample)
EP (2) EP1991678B2 (enExample)
JP (2) JP5473336B2 (enExample)
CA (1) CA2642152C (enExample)
DK (2) DK1991678T4 (enExample)
ES (2) ES2553284T5 (enExample)
PT (2) PT1991678E (enExample)
WO (1) WO2007095316A2 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1078053B1 (en) * 1998-05-14 2005-09-28 Coley Pharmaceutical GmbH METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
ATE335510T1 (de) 1998-05-22 2006-09-15 Ottawa Health Research Inst Methoden und produkte zur induzierung mukosaler immunität
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
US8834900B2 (en) * 2001-08-17 2014-09-16 University Of Iowa Research Foundation Combination motif immune stimulatory oligonucleotides with improved activity
US8153141B2 (en) * 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
MXPA05004588A (es) * 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
WO2004053104A2 (en) * 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
WO2004100965A1 (ja) * 2003-05-15 2004-11-25 Japan Science And Technology Agency 免疫刺激剤
MXPA05013922A (es) * 2003-06-20 2006-02-24 Coley Pharm Group Inc Antagonistas de receptor tipo toll de molecula pequena.
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
BRPI0416079A (pt) * 2003-10-30 2007-01-02 Coley Pharm Gmbh análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada
TW200533750A (en) * 2004-02-19 2005-10-16 Coley Pharm Group Inc Immunostimulatory viral RNA oligonucleotides
JP2008501807A (ja) * 2004-06-08 2008-01-24 コーリー ファーマシューティカル ゲーエムベーハー 抗原ならびに免疫活性化アゴニストおよび免疫活性化アンタゴニストのための担体基本骨格としての無塩基オリゴヌクレオチド
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2006091915A2 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
CN101268101A (zh) * 2005-07-07 2008-09-17 科利制药集团公司 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
JP2010503608A (ja) * 2005-09-16 2010-02-04 コーリー ファーマシューティカル ゲーエムベーハー ホスホジエステルバックボーンを有する免疫刺激性一本鎖リボ核酸
US20090306177A1 (en) * 2005-09-16 2009-12-10 Coley Pharmaceutical Gmbh Modulation of Immunostimulatory Properties of Short Interfering Ribonucleic Acid (Sirna) by Nucleotide Modification
WO2007062107A2 (en) 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
US9315536B2 (en) * 2006-08-29 2016-04-19 Creatrone, Inc. Self-assembling oligonucleotides and methods
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
PT2170353E (pt) * 2007-05-18 2015-09-16 Adiutide Pharmaceuticals Gmbh Análogos de oligonucleotídeo modificados por fosfato com atividade imunoestimulante
RU2010112771A (ru) * 2007-10-09 2011-11-20 Коули Фармасьютикал ГмбХ (DE) Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки
US8349812B2 (en) * 2007-11-06 2013-01-08 Adiutide Pharmaceuticals Gmbh Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
NZ616745A (en) * 2008-07-18 2014-06-27 Oncogenex Tech Inc Antisense formulation
AU2009311753B2 (en) 2008-11-04 2015-01-15 Index Pharmaceuticals Ab Compounds and methods for the treatment of inflammatory diseases of the CNS
RU2015151857A (ru) 2008-12-02 2019-01-15 Уэйв Лайф Сайенсес Джапан, Инк. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
MX2011010050A (es) 2009-03-25 2011-12-14 Univ Texas Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
CN103977394B (zh) 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
WO2011011431A1 (en) * 2009-07-22 2011-01-27 Ibis Biosciences, Inc. Compositions for use in identification of caliciviruses
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
AU2013209887B2 (en) 2012-01-16 2021-02-18 Elizabeth Mckenna Compositions and methods for the treatment of hepatic diseases and disorders
JP2014012650A (ja) * 2012-07-05 2014-01-23 Nihon Univ 上皮バリア機能の増強方法及び増強剤
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CA2879023C (en) 2012-07-13 2017-03-28 Wave Life Sciences Japan Asymmetric auxiliary group
JP2015535829A (ja) 2012-09-21 2015-12-17 マッケーナ、エリザベス 天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US20150037787A1 (en) * 2013-07-31 2015-02-05 International Business Machines Corporation Polynucleotide configuration for reliable electrical and optical sensing
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (ja) * 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3238727B1 (en) * 2014-12-25 2023-01-18 National Institutes of Biomedical Innovation, Health and Nutrition Non-aggregating immunostimulatory oligonucleotides
CA2972757A1 (en) 2014-12-31 2016-07-07 Arthur M. Krieg Combination tumor immunotherapy
ES2950822T3 (es) * 2015-01-16 2023-10-13 Zoetis Services Llc Vacuna contra la enfermedad de fiebre aftosa
JP6840332B2 (ja) * 2015-07-09 2021-03-10 国立研究開発法人物質・材料研究機構 免疫刺激オリゴヌクレオチド複合体
CN108713061B (zh) * 2016-03-09 2022-04-05 学校法人东京理科大学 Rna杂交形成用核酸低聚物
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
DK3700564T3 (da) 2017-12-15 2025-11-10 Elanco Animal Health Gmbh Immunostimulerende sammensætninger
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
EP3775218A1 (en) 2018-04-09 2021-02-17 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
WO2019204226A1 (en) * 2018-04-16 2019-10-24 University Of Massachusetts Compositions and methods for improved gene editing
US20220195510A1 (en) * 2019-02-12 2022-06-23 Biocartis Nv Protocols and kits for multiplex amplification and ngs-specific tagging
EP3966331A4 (en) * 2019-05-10 2023-07-05 Microbio (Shanghai) Co., Ltd. DIMER CPG OLIGONUCLEOTIDES FOR USE IN MODULATION OF IMMUNE RESPONSE
WO2020257684A1 (en) 2019-06-20 2020-12-24 University Of Massachusetts Compositions and methods for improved gene editing
EP4153752A4 (en) * 2020-05-22 2025-10-01 Harvard College INTERFERON-INDUCING OLIGONUCLEOTIDE DUPLEXES AND METHODS OF USE
WO2023034278A1 (en) * 2021-08-31 2023-03-09 President And Fellows Of Harvard College Interferon- inducing complexes and rna duplexes and methods of use

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009A (en) * 1841-03-18 Improvement in machines for boring war-rockets
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US2007A (en) * 1841-03-16 Improvement in the mode of harvesting grain
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
WO1983001451A1 (en) 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5859231A (en) 1993-09-03 1999-01-12 Duke University Synthesis of oligonucleotides with boranophosphonate linkages
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US5596091A (en) * 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
NZ332669A (en) 1996-04-29 1999-02-25 Dura Pharma Inc A dry power inhalation system which is flow rate independent
ATE292980T1 (de) * 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5888737A (en) * 1997-04-15 1999-03-30 Lynx Therapeutics, Inc. Adaptor-based sequence analysis
DE69838294T2 (de) * 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
ATE432348T1 (de) * 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
WO1999001154A1 (en) * 1997-07-03 1999-01-14 University Of Iowa Research Foundation Method for inhibiting immunostimulatory dna associated responses
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
EP1078053B1 (en) * 1998-05-14 2005-09-28 Coley Pharmaceutical GmbH METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
WO2000006588A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
WO2000016804A1 (en) * 1998-09-18 2000-03-30 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
US6207819B1 (en) * 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
UA77152C2 (en) * 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
WO2001055341A2 (en) * 2000-01-31 2001-08-02 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
EP1267618A1 (en) * 2000-03-28 2003-01-02 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
US7534772B2 (en) * 2000-06-22 2009-05-19 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
AU2002248185A1 (en) * 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7176296B2 (en) * 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
AU2002345847B2 (en) * 2001-06-21 2008-05-29 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US8834900B2 (en) 2001-08-17 2014-09-16 University Of Iowa Research Foundation Combination motif immune stimulatory oligonucleotides with improved activity
JP2005523878A (ja) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション リガンド・免疫原物質複合体を用いた処置方法
CA2483012C (en) * 2002-04-22 2011-05-24 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
AU2003243409A1 (en) * 2002-06-05 2003-12-22 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
MXPA05004588A (es) * 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
CA2512484A1 (en) * 2003-01-16 2004-05-08 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
DE602004021569D1 (de) 2003-03-07 2009-07-30 Univ New Jersey Med Optisch dekodierbare mikroträger, arrays und verfahren
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
EP2371834B1 (en) * 2003-06-11 2016-02-17 Idera Pharmaceuticals, Inc. Stabilized immunomodulatory oligonucleotides
KR101126030B1 (ko) * 2003-07-15 2012-03-19 이데라 파마슈티칼즈, 인코포레이티드 사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
BRPI0416079A (pt) * 2003-10-30 2007-01-02 Coley Pharm Gmbh análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
CN1918293A (zh) * 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
WO2005111057A2 (en) * 2004-04-02 2005-11-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing il-10 responses
HUE036894T2 (hu) * 2004-06-15 2018-08-28 Idera Pharmaceuticals Inc Immunstimuláló oligonukleotid multimerek
US7427405B2 (en) * 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
KR20100018029A (ko) * 2004-07-18 2010-02-16 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제
JP2008506683A (ja) * 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US8404829B2 (en) * 2005-01-25 2013-03-26 The Regents Of The University Of California Predictive and therapeutic markers in ovarian cancer
WO2006091915A2 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP1874325A2 (en) * 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
US20070093439A1 (en) * 2005-10-25 2007-04-26 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US9917100B2 (en) 2015-11-20 2018-03-13 Sandisk Technologies Llc Three-dimensional NAND device containing support pedestal structures for a buried source line and method of making the same

Also Published As

Publication number Publication date
CA2642152C (en) 2016-11-01
WO2007095316A2 (en) 2007-08-23
PT1991678E (pt) 2015-11-25
EP1991678B2 (en) 2020-07-15
EP1991678B1 (en) 2015-09-09
JP5473336B2 (ja) 2014-04-16
CA2642152A1 (en) 2007-08-23
EP2405002B1 (en) 2014-09-24
DK2405002T3 (en) 2015-01-05
EP1991678A2 (en) 2008-11-19
PT2405002E (pt) 2015-01-05
ES2553284T3 (es) 2015-12-07
ES2553284T5 (es) 2021-08-31
JP2014011998A (ja) 2014-01-23
EP2405002A1 (en) 2012-01-11
JP2009528027A (ja) 2009-08-06
DK1991678T3 (en) 2015-11-16
US20180171338A1 (en) 2018-06-21
WO2007095316A3 (en) 2008-03-27
JP6434204B2 (ja) 2018-12-05
US20080045473A1 (en) 2008-02-21
ES2526879T3 (es) 2015-01-16

Similar Documents

Publication Publication Date Title
DK1991678T4 (da) Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
DK3263589T5 (da) Peptidsekvenser og sammensætninger
GB2435419B (en) Formulations
DK3207941T6 (da) Fremgangsmåder og sammensætninger baseret på diphtheritoksin-interleukin-3-konjugater
EP2046930A4 (en) FORMULATIONS BASED ON RHAMNOLIPIDS
DK2069352T3 (da) Bestemte kemiske enheder, sammensætninger og fremgangsmåder
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2001497A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0713625D0 (en) Pharmaceutical compositions
EP2124556A4 (en) PHARMACEUTICAL COMPOSITIONS
IL217840A0 (en) Long lasting drug formulations
DK2034015T3 (da) Immunstimulerende oligonucleotid og farmaceutisk anvendelse heraf
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
DK1978944T3 (da) Blød-gelatine-kapselformulering
GB0718409D0 (en) Formulations
GB0605780D0 (en) Formulations
DK3263112T3 (da) Sammensætninger og fremgangsmåder til undertrykkelse af endometriproliferationer
EP2185112A4 (en) Stabilized therapeutic compositions and formulations
DK1971633T3 (da) Indpakkkede detergentsammensætninger og fremgangsmåde til deres fremstilling
EP2101736A4 (en) HOMOGENEOUS PULP AND GEL PREPARATIONS
GB0610336D0 (en) Formulations
IL198160A0 (en) Pharmaceutical formulations
ITMI20061291A1 (it) Composizioni (per) fluoroelastomeriche
DK2114424T3 (da) Betalain-faststofsammensætninger og fremgangsmåder
DK2069494T3 (da) Cellulase-frie enzymsammensætninger og værtsceller til fremstilling heraf